EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incidence and Relative Survival of Patients with Merkel Cell Carcinoma in North Rhine-Westphalia, Germany, 2008–2021

Andreas Stang iD, Lennart Möller iD, Ina Wellmann iD, Kevin Claaßen iD, Hiltraud Kajüter iD, Selma Ugurel iD, Jürgen C Becker iD

Cancers · 06.06.2024 · 16 (11) · 2158

DOI: 10.3390/cancers16112158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 06.06.2024. Verfasst von Andreas Stang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To date, only a few population-representative studies have been carried out on the rare Merkel cell carcinoma (MCC). We provide incidence and survival estimates of MCC, including the conditional relative survival.

Methods

We analyzed data from the cancer registry of North Rhine-Westphalia, Germany, 2008–2021, covering a population of 18 million. We included all newly diagnosed MCCs and calculated age-standardized (old European Standard population) incidence rates and unconditional and conditional relative survival.

Results

Our analysis included 2164 MCC patients. The age-standardized incidence of MCC was 5.2 (men) and 3.8 (women) per million person-years. The 5-year relative survival was 58.8% (men) and 70.7% (women). Survival was lower among men than women in all age–sex groups and was highest for MCC of the upper extremity in both men (68.2%) and women (79.3%). The sex difference in survival is particularly due to the better survival of women with MCC of the head and neck. In terms of survival, the first two years are particularly critical.

Conclusions

Our data validate the worse survival among men and highlights a more favorable prognosis for MCCs located on the limbs. The first two years after diagnosis of MCC are the years with the highest excess mortality.

Schlagwörter

Stichwörter der Autor:innen

(MeSH) carcinomaGermanyMerkel cellincidenceregistriessurvival analysis

Autor:innen und Institutionen

  • Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany.
  • School of Public Health, Department of Epidemiology, Boston University, 715 Albany St, Boston, MA 02118, USA.
  • Cancer Registry of North Rhine-Westphalia, Gesundheitscampus 10, 44801 Bochum, Germany.
  • Department of Dermatology, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany.
  • German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Hufelandstr. 55, 45147 Essen, Germany.
  • Translational Skin Cancer Research, University Medicine Essen, Hufelandstr. 55, 45147 Essen, Germany.

ORCID-Profile: Andreas Stang, Lennart Möller, Ina Wellmann, Kevin Claaßen, Hiltraud Kajüter, Selma Ugurel, Jürgen C Becker

Zitieren

APA

Stang, A., Möller, L., Wellmann, I., Claaßen, K., Kajüter, H., Ugurel, S., & Becker, J. C. (2024). Incidence and Relative Survival of Patients with Merkel Cell Carcinoma in North Rhine-Westphalia, Germany, 2008–2021. Cancers, 16(11), 2158. https://doi.org/10.3390/cancers16112158

Vancouver

Stang A, Möller L, Wellmann I, Claaßen K, Kajüter H, Ugurel S, et al. Incidence and Relative Survival of Patients with Merkel Cell Carcinoma in North Rhine-Westphalia, Germany, 2008–2021. Cancers. 2024;16(11):2158. doi:10.3390/cancers16112158

BibTeX
@article{Stang2024,
  author = {Stang, Andreas and Möller, Lennart and Wellmann, Ina and Claaßen, Kevin and Kajüter, Hiltraud and Ugurel, Selma and Becker, Jürgen C},
  title = {Incidence and Relative Survival of Patients with Merkel Cell Carcinoma in North Rhine-Westphalia, Germany, 2008–2021},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {11},
  pages = {2158},
  doi = {10.3390/cancers16112158}
}
Kostenlos starten →